ArticleAnnals of hematology2026

Between the classic hit and the modern sequel: transition dosing between peginterferon alfa-2a and ropeginterferon alfa-2b for myeloproliferative neoplasms.

Ghaith Abu-Zeinah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.